Caris Life Sciences, Inc. Common Stock (CAI) - Total Liabilities
Based on the latest financial reports, Caris Life Sciences, Inc. Common Stock (CAI) has total liabilities worth $637.89 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Caris Life Sciences, Inc. Common Stock liquidity resilience to evaluate the company's liquid asset resilience ratio.
Caris Life Sciences, Inc. Common Stock - Total Liabilities Trend (2003–2025)
This chart illustrates how Caris Life Sciences, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Caris Life Sciences, Inc. Common Stock.
Caris Life Sciences, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Caris Life Sciences, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hellenic Telecommunications Organization S.A
AT:HTO
|
Greece | €3.07 Billion |
|
Fluor Corporation
NYSE:FLR
|
USA | $4.75 Billion |
|
CarMax Inc
NYSE:KMX
|
USA | $20.48 Billion |
|
Blue Owl Capital Inc
NYSE:OWL
|
USA | $-6.18 Billion |
|
ASX LTD UNSPONS.ADR 1
F:AUX1
|
Germany | €13.70 Billion |
|
Jiangsu Leadmicro Nano Technology Co. Ltd. A
SHG:688147
|
China | CN¥5.54 Billion |
|
Ringkjoebing Landbobank A/S
CO:RILBA
|
Denmark | Dkr79.30 Billion |
|
Bank of India
NSE:BANKINDIA
|
India | Rs10.89 Trillion |
Liability Composition Analysis (2003–2025)
This chart breaks down Caris Life Sciences, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Caris Life Sciences, Inc. Common Stock (CAI) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Caris Life Sciences, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Caris Life Sciences, Inc. Common Stock (2003–2025)
The table below shows the annual total liabilities of Caris Life Sciences, Inc. Common Stock from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $548.36 Million | -80.71% |
| 2024-12-31 | $2.84 Billion | +11.13% |
| 2023-12-31 | $2.56 Billion | +5.72% |
| 2022-12-31 | $2.42 Billion | +26.65% |
| 2020-12-31 | $1.91 Billion | -13.50% |
| 2019-12-31 | $2.21 Billion | -4.45% |
| 2018-12-31 | $2.31 Billion | +23.84% |
| 2017-12-31 | $1.87 Billion | +16.77% |
| 2016-12-31 | $1.60 Billion | +4.80% |
| 2015-12-31 | $1.53 Billion | +12.74% |
| 2014-12-31 | $1.35 Billion | +7.34% |
| 2013-12-31 | $1.26 Billion | +21.07% |
| 2012-12-31 | $1.04 Billion | +47.75% |
| 2011-12-31 | $704.63 Million | +69.47% |
| 2010-12-31 | $415.78 Million | +69.72% |
| 2009-12-31 | $244.99 Million | -18.02% |
| 2008-12-31 | $298.84 Million | +31.10% |
| 2007-12-31 | $227.95 Million | -10.69% |
| 2006-12-31 | $255.25 Million | +72.85% |
| 2005-12-31 | $147.67 Million | -6.62% |
| 2004-12-31 | $158.14 Million | -11.12% |
| 2003-12-31 | $177.92 Million | -- |
About Caris Life Sciences, Inc. Common Stock
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exom… Read more